Djordje Atanackovic

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Shaji Kumar, Natalie S. Callander, Melissa Alsina et al. · Journal of the National Comprehensive Cancer Network · 2017 · 280 citations · Full text

Medicine, Hematology, Oncology +17

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 253 citations · Full text

Medicine, Oncology, Pharmacology +12

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Fredrik Schjesvold, Albert Oriol, Lionel Karlin et al. · The Lancet Haematology · 2019 · 242 citations · Full text

Medicine, Oncology, Pharmacology +11

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer

Martin Sebastian, Andreas Schröder, Birgit Scheel et al. · Cancer Immunology Immunotherapy · 2019 · 204 citations · Full text

Medicine, Immunology, Oncology +12

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018

Shaji Kumar, Natalie S. Callander, Melissa Alsina et al. · Journal of the National Comprehensive Cancer Network · 2018 · 203 citations · Full text

Medicine, Hematology, Oncology +15